You are invited to join us at the Food and Drug Law Journal 2022 Symposium – a special event. George O’Brien, partner in Mayer Brown’s Life Science Industry Group, will discuss his upcoming paper “FDA and the PTO: There is a role beyond the ‘ministerial’ for the FDA in managing the Orange Book and other parts of the Hatch-Waxman Patent Regime. ?” on November 3rd.
The panel will discuss:
- The implications of recent communications between the FDA and the PTO to address the effects of patents on competition;
- Usage Law, Part viii information and engraved marks, and the effect of GSK v. Teva results;
- Recent rulings regarding the listing of certain medical device and REMS patents, and the FDA’s response; and
- New information related to patent term extensions pending FDA decisions.
The panel will be held on Thursday, November 3, 2022
11:20 am –12:35 pm EDT
To learn more and register, please visit the website.